Skip to main content
. 2019 Oct 15;59(11):3337–3349. doi: 10.1111/trf.15540

Table 1.

Meta‐analyses on the exposure to allogeneic blood products in the included studies

Transfusion ratio Blood product exposure (units) Pooled mean difference 95% CI p (overall effect) I2
RCTs
FFP:PLTs:RBCs 1:1:1 vs. <1:1:1 RBCs –0.65 –1.75 to 0.45 0.25 0%
FFP:PLTs:RBCs 1:1:1 vs. <1:1:1 FFP 1.91 0.92 to 2.90 0.0002 0%
FFP:PLTs:RBCs 1:1:1 vs. <1:1:1 PLTs 3.28 –2.66 to 9.23 0.28 87%
Observational cohort studies
FFP:RBCs 1:1 vs. <1:1 RBCs –0.68 –2.68 to 1.33 0.51 59%
FFP:RBCs 1:1 vs. <1:1 FFP 8.88 3.76 to 14.0 0.0007 95%
FFP:RBCs 1:1 vs. <1:1 PLTs 0.80 –0.75 to 2.36 0.31 84%
FFP:RBCs 1:1.5 vs. <1:1.5 RBCs –0.26 –6.28 to 5.76 0.93 98%
FFP:RBCs 1:1.5 vs. <1:1.5 FFP 9.65 5.35 to 13.95 < 0.0001 98%
FFP:RBCs 1:1.5 vs. <1:1.5 PLTs 1.04 –0.48 to 2.55 0.18 88%
FFP:RBCs 1:2 vs. <1:2 RBCs –1.12 –4.27 to 2.03 0.48 91%
FFP:RBCs 1:2 vs. <1:2 FFP 9.24 3.95 to 14.53 0.0006 98%
FFP:RBCs 1:2 vs. <1:2 PLTs 7.82 –2.83 to 18.47 0.15 98%
PLTs:RBCs 1:1 vs. <1:1 RBCs –0.39 –5.121 to 4.32 0.87 86%